Welcome to the Premarin® Class Action Website

This website provides general information on Class Actions
involving the brand-name drug Premarin®

IF YOU PURCHASED OR PAID FOR PREMARIN® IN CALIFORNIA FROM MARCH 24, 1999 TO APRIL 3, 2007, A PROPOSED CLASS ACTION SETTLMENT MAY AFFECT YOUR RIGHTS.

The Superior Court of the State of California for the County of San Francisco entered an order granting Plaintiff’s Motion for Class Certification and on April 10, 2007, the Court entered an Order Granting Preliminary Approval of a Settlement, Directing Notice to the Class and Schedule Fairness Hearing.

Description of the Lawsuit

Premarin® is a conjugated estrogens product prescribed by doctors to relieve the symptoms associated with menopause and to prevent osteoporosis in postmenopausal women. Plaintiff alleges that the manufacturers Wyeth Pharmaceuticals (formerly Wyeth-Ayerst Laboratories, Inc.) and Wyeth (formerly American Home Products Corporation) violated California’s antitrust and unfair competition laws by engaging in anti-competitive and exclusionary conduct that blocked consumer access to Cenestin®, which was an alternative to Premarin®. Plaintiff does not challenge the safety or effectiveness of Premarin®.

FOR ADDITIONAL INFORMATION ON THE CALIFORNIA CLASS ACTION, PLEASE CLICK ON THE CALIFORNIA TAB.

IF YOU PURCHASED OR PAID FOR PREMARIN® IN ARIZONA, FLORIDA, IOWA, KANSAS, MAINE, MASSACHUSETTS, MICHIGAN, MINNESOTA, MISSISSIPPI, NEW MEXICO, NORTH CAROLINA, NORTH DAKOTA, SOUTH DAKOTA, TENNESSEE, VERMONT, WEST VIRGINIA AND WISCONSIN SINCE MARCH 24, 1999 OR IN NEVADA SINCE OCTOBER 1, 1999, THIS MAY AFFECT YOUR RIGHTS.

The United States District Court for the Southern District of Ohio, Western Division entered an order giving preliminary approval of a Settlement.

Description of the Lawsuit

Premarin® is a conjugated estrogens product prescribed by doctors to relieve the symptoms associated with menopause and to prevent osteoporosis in postmenopausal women. Plaintiffs alleges that the manufacturers Wyeth Pharmaceuticals (formerly Wyeth-Ayerst Laboratories, Inc.) and Wyeth (formerly American Home Products Corporation) violated federal antitrust and the state antitrust, unfair competition, and unjust enrichment laws in certain states by engaging in anti-competitive and exclusionary conduct that blocked consumer access to Cenestin®, another estrogen therapy product. Plaintiffs does not challenge the safety or effectiveness of Premarin®.

FOR ADDITIONAL INFORMATION ON THE OHIO CLASS ACTION, PLEASE CLICK ON THE OHIO TAB.